Main Street Financial Solutions LLC Has $231,000 Holdings in Danaher Corporation $DHR

Main Street Financial Solutions LLC cut its holdings in Danaher Corporation (NYSE:DHR) by 70.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,213 shares of the conglomerate’s stock after selling 2,911 shares during the period. Main Street Financial Solutions LLC’s holdings in Danaher were worth $231,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of DHR. BlackRock Inc. acquired a new position in shares of Danaher during the 2nd quarter worth approximately $10,492,520,000. Norges Bank bought a new stake in Danaher during the fourth quarter valued at $2,177,106,000. Bank of New York Mellon Corp bought a new stake in shares of Danaher in the 2nd quarter valued at $712,875,000. Viking Global Investors LP raised its stake in Danaher by 543.9% during the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock worth $574,351,000 after buying an additional 2,455,994 shares during the period. Finally, Deutsche Bank AG acquired a new position in shares of Danaher during the second quarter valued at about $446,265,000. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on DHR shares. Stifel Nicolaus decreased their price objective on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Jefferies Financial Group reissued a “buy” rating and issued a $245.00 target price on shares of Danaher in a research report on Tuesday, April 21st. TD Cowen cut their target price on Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Guggenheim lowered their target price on shares of Danaher from $235.00 to $200.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Finally, HSBC reduced their target price on shares of Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $228.91.

Danaher Price Performance

Danaher stock opened at $199.62 on Wednesday. The company has a fifty day simple moving average of $193.74 and a 200-day simple moving average of $192.50. The firm has a market capitalization of $140.33 billion, a price-to-earnings ratio of 35.46, a PEG ratio of 2.52 and a beta of 0.78. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.77 EPS. On average, equities analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.